BT and Tech Mahindra today announced that both companies will work together to help life sciences enterprises improve their productivity and efficiency through cloud services. Ovum forecasts the life sciences industry will spend US$40.8bn by 2017 on IT in the areas of clinical trials, supply chain, business intelligence and analytics.
Tech Mahindra becomes a Strategic Member of the BT for Life Sciences partner ecosystem. Initially, this enables both companies to offer proof of concept trials to global pharmaceuticals, contract research organizations, government health organizations, and healthcare providers.
The co-operation between both companies will cover the UK, the US, Western Europe, India and Asia Pacific territories. Life Sciences customers will benefit from specific Tech Mahindra and BT products and services via joint go-to-market activities.
Tech Mahindra’s Life Sciences practice capabilities will be aligned with the existing BT for Life Sciences services, offering more comprehensive end-to-end solutions for clients.
The combination of Tech Mahindra IT Services and Business Services Group (BSG) capabilities with the BT for Life Sciences platform facilitates a number of scenarios for the industry. These scenarios include faster in-silico discovery and research; removing the IT complexities surrounding gene sequencing programmes; more efficient drug manufacturing; deriving insight from large health datasets; patient stratification; and adherence to regulatory requirements.
“The timing of this relationship is ideal since many global Life Sciences firms are beginning to seriously evaluate cloud solutions for future proofing and cost effectiveness,” stated Dipankar Mitra, Global Head, Healthcare and Life Sciences, Tech Mahindra. “We are looking forward to working with BT to capitalize on this market opportunity”
“We want to provide Life Sciences companies with the technology to bring potentially life-saving products to market faster,” said Yury Rozenman, Business Development Director, BT for Life Sciences. “By combining the BT for Life Sciences solutions with Tech Mahindra’s capabilities, we will be able to go-to-market more effectively with a secure and compliant cloud service that can enhance the drug discovery and development cycle.”
BT for Life Sciences was developed as a secure and segregated platform, using BT Cloud Compute. It allows scientists to construct and orchestrate in-silico workflows and data pipelines so that new pharmaceutical targets and drug candidates can be identified. This platform enables research scientists to create global project groups and collaborate using social media tools. This ecosystem allows them to securely upload documents, share results and communicate via IM, voice, video, or chat. They can also analyze results in an environment that segments data and uses qualified hardware components and workflows specific to the pharmaceutical industry. The BT for Life Sciences platform enables organizations to adhere to GxP quality and regulatory compliance requirements. This is particularly important when collaborating across partner organizations, all of which may have different risk profiles and operate in diverse, regulated environments.
Tech Mahindra’s Life Sciences practice offers a wide range of innovative solutions for effectively managing the drug discovery, development, manufacturing, marketing and sales processes.